Long-term effect of the women's health initiative study on antiosteoporosis medication prescribing

Journal of Women's Health

Volumn 19, Issue 5, 2010, Pages 847-854

  Lee, Euni ^a,b   Maneno, Mary K ^a   Wutoh, Anthony K ^a   Zuckerman, Ilene H ^c  

^a HOWARD UNIVERSITY   (United States)

^b Chonnam National University   (South Korea)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; PARATHYROID HORMONE[1-34]; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

AFRICAN AMERICAN; AGE; AMBULATORY CARE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; ESTROGEN THERAPY; GEOGRAPHIC DISTRIBUTION; MEDICAID; OSTEOPOROSIS; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; TIME SERIES ANALYSIS; TREND STUDY;

ADULT; BONE DENSITY CONSERVATION AGENTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LINEAR MODELS; MIDDLE AGED; OSTEOPOROSIS; PHYSICIAN'S PRACTICE PATTERNS; WOMEN'S HEALTH; WOMEN'S HEALTH SERVICES; YOUNG ADULT;

EID: 77952374262     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2009.1441     Document Type: Article

References (43)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
2. Prempro package insert. Available at www.accessdata.fda.gov=Scripts=cder= DrugsatFDA=Accessed July 1, 2009.
3. Hillman JJ, Zuckerman IH, Lee E. The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program. J Womens Health 2004;13:986-992.
4. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 2004;292:1983-1988.
5. McIntosh J, Blalock S. Effects of media coverage of Women's Health Initiative study on attitudes and behavior of women receiving hormone replacement therapy. Am J Health Syst Pharm 2005;62:69-74.
6. Bestul MB, McCollum M, Hansen LB, Saseen JJ. Impact of the Women's Health Initiative trial results on hormone replacement therapy. Pharmacotherapy 2004;24:495-499.
7. Hersh AL, Stefanick ML, Stafford RS. National use of post-menopausal hormone therapy annual trends and responses to recent evidence. JAMA 2004;291:47-53.
8. Hass JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004;140:184-188.
9. Watson J, Wise L, Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 2007;63:843-849.
10. Udell JA, Fischer MA, Brookhart MA, Solomon DH, Choudhry NK. Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res 2006;21:765-771.
11. Usher C, Teeling M, Bennett K, Feely J. Effect of clinical trial publicity on HRT prescribing in Ireland. Eur J Clin Pharmacol 2006;62:307-310.
12. Huang WF, Tsai YW, Hsiao FY, Liu WC. Changes of the prescription of hormone therapy in menopausal women: An observational study in Taiwan. BMC Public Health 2007;7:56.
13. Thunell L, Milsom I, Schmidt J, Mattsson LA. Scientific evidence changes prescribing practice - A comparison of the management of the climacteric and use of hormone replacement therapy among Swedish gynaecologists in 1996 and 2003. Br J Obstet Gynaecol 2006;113:15-20.
14. Lee E, Wutoh AK, Xue Z, Hillman J, Zuckerman IH. Osteoporosis management after the Women's Health Initiative study in a Medicaid population. J Womens Health 2006;15: 155-161.
15. Lazar F Jr, Costa-Paiva L, Morais SS, Pedro AO, Pinto-Neto AM. The attitude of gynecologists in Sao Paulo, Brazil, 3 years after the Women's Health Initiative study. Maturitas 2007;56:129-141.
16. Kang BM, Kim MR, Park HM, et al. Attitudes of Korean clinicians to postmenopausal hormone therapy after the Women's Health Initiative study. Menopause 2006;13:125-129.
17. Stafford RS, Drieling RL, Hersh AL. National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Med 2004;164:1525-1530.
18. Parente L, Uyehara C, Larsen W, Whitcomb B, Farley J. Long-term impact of the Women's Health Initiative study on HRT. Arch Gynecol Obstet 2008; 277:219-224.
19. Huot L, Couris CM, Tainturier V, Jaglal S, Colin C, Schott AM. Trends in HRT and antiosteoporosis medication prescribing in European population after the WHI study. Osteoporos Int 2008;19:1047-1054.
20. Farley JF, Blalock SJ, Cline RR. Effect of the Women's Health Initiative on prescription antiosteoporosis medication utilization. Osteoporos Int 2008;19:1603-1612.
21. Wysowski DK, Governale LA. Use of menopausal hormones in the United States. Pharmacoepidemiol Drug Saf 2005;14: 171-176.
22. Kelly JP, Kelly JP, Kaufman DW, et al. Use of postmenopausal hormone therapy since the Women's Health Initiative study findings. Pharmacoepidemiol Drug Saf 2005;14:837-842.
23. Ly N, McCaig L, Burt CW. National Hospital Ambulatory Medical Care Survey: 1999 Outpatient Department Summary. Advance data from vital and health statistics, No. 321. Hyattsville, MD: National Center for Health Statistics, 2001.
24. Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2005 Summary. Advance data from vital and health statistics, No. 387. Hyattsville, MD: National Center for Health Statistics, 2007.
25. Middleton K, Hing E. National Hospital Ambulatory Medical Care Survey: 2005 Outpatient Department Summary. Advance data from vital and health statistics, No. 327. Hyattsville, MD: National Center for Health Statistics, 2007.
26. Lobo RA. Menopause. In: Goldman L, Bennett JC, eds. Cecil textbook of medicine. Philadelphia: W.B. Saunders Co, 2000:1360-1366.
27. Boothby L. Bisphosphonates for the prevention and treatment of osteoporosis. P&T 2002;27:506-513.
28. IMS-Health. Total promotion reports 1998: Report TPR-2. Plymouth Meeting, PA: IMS-Health, 1999.
29. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-216.
30. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003;14:259-262.
31. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965-968.
32. McCombs JS, Thiebaud P, Mclaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-287.
33. Papaioannou A, Ionnidis G, Adachi JD, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 2003;14:808-813.
34. Weiss M, Vered I, Foldes AJ, et al. Treatment preference and tolerability with alendronate once weekly over a 3-month period: An Israeli multi-center study. Aging Clin Exp Res 2005;17:143-149.
35. Miller PD, Epstein S, Sedarati F, Reginster JY. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: Results from the head-to-head MOTION study. Curr Med Res Opin 2008;24:207-213.
36. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of post-menopausal osteoporosis: 2001 edition with selected updates for 2003. Endocr Pract 2003;9:544-564.
37. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602.
38. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Available at www.nof.org=professionals=NOF- Clinicians-Guide.pdf Accessed November 21, 2008.
39. Lee E, Zuckerman IH, Weiss SR. Patterns of pharmacotherapy and counseling for osteoporosis management in visits to U.S. ambulatory care physicians by women. Arch Intern Med 2002;162:2362-2366.
40. Farley JF, Cline RR, Gupta K. Racial variations in anti-resorptive medication use: Results from the 2000 Medical Expenditure Panel Survey (MEPS). Osteoporos Int 2006; 17:395-404.
41. Brown AF, Pérez-Stable EJ, Whitaker EE, et al. Ethnic differences in hormone replacement prescribing patterns. J Gen Intern Med 1999;14:663-669.
42. Marsh JV, Brett KM, Miller LC. Racial differences in hormone replacement therapy prescriptions. Obstet Gynecol 1999;93:999-1003.
43. Weng HH, McBride CM, Bosworth HB, Grambow SC, Siegler IC, Bastian LA. Racial differences in physician recommendation of hormone replacement therapy. Prev Med 2001;33:668-673.